Original Article
International Journal of Impotence Research (2008) 20, 307–314; doi:10.1038/ijir.2008.1; published online 14 February 2008
Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model
J E Dall'Era1, R B Meacham1, J N Mills1, S Koul1, S N Carlsen1, J B Myers1 and H K Koul1,2
- 1Signal Transduction and Molecular Urology Laboratory, Program in Urosciences, Division of Urology—Department of Surgery, School of Medicine, Denver, Colorado, USA
- 2University of Colorado Comprehensive Cancer Center, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA
Correspondence: Dr HK Koul, Department of Surgery-Division of Urology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box C319, Denver, CO 80262, USA. E-mail: Hari.koul@uchsc.edu
Received 2 August 2007; Revised 3 December 2007; Accepted 22 December 2007; Published online 14 February 2008.
Abstract
Erectile dysfunction (ED) is a cause of decreased quality of life in more than 70% of diabetic men. Vascular endothelial growth factor (VEGF) has shown to improve overall endothelial and smooth muscle cell dysfunction in models of ED. We describe a novel technique for nonviral, in vivo gene transfection of VEGF in the rat corpus cavernosum. Diabetic rats were transfected with DNA encoding a fusion VEGF/green fluorescent protein (GFP) complex and fluorescence microscopy was used to monitor the expression of VEGF–GFP fusion protein. Western blot and PCR analyses confirmed the expression of the GFP–VEGF fusion protein and mRNA. Functional studies using cavernous nerve stimulation revealed maximal intracavernous pressures (ICPs) of 63.1 mm Hg, and 30.7 mm Hg in the normal and diabetic control groups, respectively, and 47.4 mm Hg in VEGF–GFP-transfected diabetic group. Immunohistochemical analysis of the cavernosal tissue from transfected rats showed increased smooth muscle content compared with the diabetic control group. We show for the first time in our animal model that expression of the transfected VEGF in cavernosal tissue leads to an overall improvement of maximal ICP and smooth muscle content. On the basis of these results, it is tempting to speculate that our nonviral vector system offers an excellent system for gene delivery into cavernosal tissue, and that VEGF gene therapy using this system could be useful in improving erectile function in diabetic men.
Keywords:
gene therapy, erectile dysfunction, diabetic model, VEGF
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Protein palmitoylation: a regulator of neuronal development and function
Nature Reviews Neuroscience Review (01 Oct 2002)
PI3K pathway alterations in cancer: variations on a theme
Oncogene Review
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B
Oncogene Original Article
Molecular Therapy Original Article
Asian Journal of Andrology Original Article
